Anti-Mouse RANKL (CD254) – Purified in vivo PLATINUM™ Functional Grade
Pricing & Details
Purified Recombinant Mouse RANKL (NSO-derived)
≥ 5.0 mg/ml
≤ 0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUMTM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for RANKL antibody, clone IK22/5 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this RANKL antibody for use in western blotting is 1-10 μg/ml.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone IK22/5 recognizes an epitope on mouse RANKL.
RANKL is expressed on activated T cells and osteoclasts.
RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
NCBI Gene Bank ID
References & Citations
1. Park JH, et al. (2017) Mol Cells. 40(10):706-713
2. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-4
3. Anderson, D. M., et al. (1997) Nature 390:175.
4. Ono T, et al. (2020) Inflamm Regen. 2020;40:2.
5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28